Biotech Values

[DewDiligence]

AZN—DANUBE phase-3 study in first-line bladder cancer fails both primary endpoints: i) Infinzi/tremelimumab (CTLA4) did not show statsig-better OS than chemotherapy alone in patients regardless of PD-L1 expression; and ii) Infinzi monotherapy did not show statsig-better OS than chemotherapy alone in patients with PD-L1>=25%.

https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html

The HR values and other study details have been withheld for presentation at an unspecified medical conference.

This result is modestly bullish for BMY.